MHRA Largest Seizure of Unlicensed Weight Loss Medicines
Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.
2 SOPs may need review
Covidien (Medtronic) recalls specific lots of MonaTherm probes due to potential incorrect temperature readings or quality defects.
Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.
Regulatory Intelligence Lead
single event
Do not use and discard any sprayers included with PhaseOne 50 ml bottles. Product units not assembled with sprayer may be used by pouring solution directly from bottle.
FDA classified the Covidien MonaTherm probe recall as Class 2 and instructed users to quarantine and return unused products.
Incorrect temperature readings could lead to misdiagnosis or inappropriate patient management, posing serious safety risks.
Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.
Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.
2 SOPs may need review
Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.
2 SOPs may need review
Ask the safety/device vigilance and PV CSV leads to: (1) confirm whether any marketed/fielded SaMD/AIaMD uses adaptive ML or planned updates that would fit a PCCP-like approach; (2) review current change-control SOPs and technical documentation to ensure change governance and transparency artifacts are captured and retrievable; (3) verify post-market/vigilance processes explicitly account for algorithm updates (e.g., monitoring after updates, escalation criteria).
5 SOPs may need review
Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.
2 SOPs may need review